VISION STATEMENT:
We envision a world where data empowers mental wellness.
MISSION STATEMENT:
To identify the link between biological markers and mental health conditions.
OUR VALUES:
HONESTY & TRANSPARENCY.
We will always act with honesty and transparency in our dealings with others.
RESPECT
We will always have regard for the feelings, wishes and rights of others.
INTEGRITY
We will always act having regard to the highest moral principles.
EXCELLENCE
We will always strive in the pursuit of excellence.
High prevalence of major depression in US sleep clinics: the need for routine depression screening in sleep services
Silvia Daccò, PsyD, Daniela Caldirola, MD, PhD, Massimiliano Grassi, PsyD, Alessandra Alciati, MD, Giampaolo Perna, MD, PhD, Archie Defillo, MD
Published Online: April 1, 2023
Abstract
Depression screening is not part of routine clinical practice in US sleep clinics. Our study aimed to report the prevalence of depression among individuals referred to US sleep clinics. According to our findings, approximately 21% of patients had depression, with about 4% reporting severe symptoms, 9% had frequent death and/or self-harming thoughts, and 61% were taking antidepressants. Our results highlighted a considerable risk of prevalent depression in sleep clinics and supported the limited existing data on this topic. Our study advocates for the need for routine depression screening in sleep services to reduce the detrimental consequences of a delayed depression diagnosis and the risk of a worse prognosis for both depression and sleep–wake disorders.
We take sleep physiology, subjects' sociodemographic and clinical characteristics, and we use AI to connect them and extract biomarkers that can map a subjects’ mental health status.
SLEEP RESEARCH - TvX Stager
Identifies the four important sleep stages of a subject and aids in the determination of sleep architecture features and mapping of autonomic function throughout the sleep stages.
SLEEP PROVIDERS - MEB-001:
MEB-001 will be a Software Medical Device that uses artificial intelligence to map a subjects' mental health.
Dr. Archie Defillo
Chief Medical Officer
Kai Sun
Chief Operating Officer
Dr. Massimiliano Grassi
Head of Artificial Intelligence
David Trimboli
Non-executive Chairman
Mr Trimboli is an experienced global investor with experience in commodities financing and trading. He has
undertaken investments activities and hold diverse interests in commodities, industrial minerals, real estate
and technology and mental health in Australia and internationally.
Mr Trimboli is the founder of Seefeld Investments with offices in London, Zug and Perth. He has formerly a long
serving senior coal trader at the world’s largest commodities trading group, Glencore International AG and was
a key member of the Glencore team when the group successfully completed its IPO in London and Hong Kong.
He currently holds a Managing Director position in Seefeld Investments Pty Ltd, Non-Executive Chairman in
Audeara Limited (ASX: AUA) and Non-Executive Director positions in the following Companies Quantum
Graphite Limited (ASX: QGL), TradeMutt, Yumm Confectionar, The Reading Switch, Carecircle and Greater
Outcomes, all being companies in revenue generating businesses with developed management teams and on
pathways to profitability.
Dr Tony Keating
Executive Director
Dr Keating was the co-founder and Chief Executive Officer of ResApp Health, a digital health company which successfully developed a groundbreaking smartphone technology for accurately diagnosing respiratory diseases based on cough analysis. Dr Keating led the ResApp team through the commercialisation of the company’s technology, commencing with a successful R&D phase through to global regulatory approvals and commercial partnerships, before overseeing the sale of the company to Pfizer in 2022 for $180m. Following the acquisition, he transitioned to the role of Vice President at Pfizer to manage the integration of ResApp’s business.
Prior to co-founding ResApp, Dr Keating was the Director of Commercial Engagement at UniQuest, the commercialisation arm of The University of Queensland (UQ) which specialises in industry university collaborations for the UQ’s in-house network of 7,000 world-class researchers. Dr Keating holds a PhD in Mechanical Engineering from The University of Queensland, and an Executive Certificate of Management and Leadership from the MIT Sloan School of Management.
